Top

Illumina and PacBio Sequencing of Human and Mouse DNA and RNA

Active

1000273702International

Response Deadline12/03/2026, 07:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Health Canada's Mechanistic Studies Division is seeking high-throughput genome sequencing services to support four research projects focused on identifying environmental mutagens and evaluating occupational hazards. The contract requires the use of Illumina and Pacific Biosciences (PacBio) Revio platforms to sequence pre-prepared DNA libraries, genomic DNA, and RNA from human and mouse samples. Key technical deliverables include whole-genome sequencing, whole-exome sequencing with a minimum mean depth of 100x, and RNA sequencing with at least 20 million reads per sample. The resulting data will be used to characterize spontaneous and induced mutations and gene expression changes to improve toxicological testing and human health risk assessments. The contract follows a lowest evaluated price selection process based on mandatory technical criteria, including the provision of a no-cost quality control portal, cloud-based software for downloading bam and fastq files for at least 90 days, and evidence of validated sequencing workflows. The initial term runs from the date of award until March 31, 2027, with the possibility of four optional one-year extensions extending the performance period to March 20, 2031. All work is to be performed at the contractor's facilities, and the contractor must ensure that all sequencing and quality control are conducted by experienced personnel. Invoices are to be submitted electronically and will be paid within 30 days of receipt.

General Info

Health Canada seeks high-throughput genome sequencing services for mutagen research through March 2031.

Agency

Government of Canada → Department of Health

NAICS

541380 - Testing Laboratories and Services

Place of Performance

Canada, Chile, Colombia, Peru, United States of America, South Korea, Honduras, Panama, Europe, CAN

Set-Aside

NONE

Documents

rfp

High

rfp

High

AI Contract Breakdown

Uniform Contract Format

Timeline

PhaseSolicitation

PostedNov 3

Solicitation

Response DeadlineDec 3

Submission deadline

Response Deadline

12/03/2026, 07:00:00 PM UTCin 30 days

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyGovernment of Canada → Department of Health

Contacts1 person available

OfficeN/A

Organization / AgencyGovernment of Canada → Department of Health

Office AddressN/A

Contacts

Wesley PhillipsContracting Authority

contact@example.gov

Full Description

The Mechanistic Studies Division (MSD) of Health Canada’s Environmental Health Research and Science Bureau investigates the pathways by which physical, chemical and microbiological agents can cause adverse health effects. To determine how chemical substances cause DNA damage that can lead to illnesses like cancer or inherited diseases, MSD requires high-throughput genome sequencing services utilizing Illumina and Pacific Biosciences (PacBio) platforms. The primary objective of this contract is to secure long-term high-quality sequencing services for pre-prepared DNA libraries and genomic DNA and/or RNA utilizing Illumina or PacBio Revio platforms for the full duration of projects funded until up to 2030-2031. This requirement encompasses the sequencing of multiple mouse and human error-corrected next-generation sequencing (ecNGS) DNA libraries, genomic DNA and/or RNA samples in direct support of four distinct research projects. These projects are distributed across the Division and funded through three separate programs. Collectively, they employ advanced genomic technologies to support public health protection by identifying environmental mutagens, evaluating occupational hazards, and improving toxicological testing methodologies. Specifically, this work will use ecNGS, whole-genome sequencing (WGS), whole-exome sequencing and/or RNA-sequencing approaches to detect and characterize both spontaneous mutations and mutations induced by chemical and environmental exposures in mouse and human DNA as well as gene expression changes. The resulting data will contribute to a better understanding of mutagenic mechanisms, exposure-related genetic damage, and the development of more sensitive and informative approaches for genetic toxicology and human health risk assessment.